The synthetic melanocortin (MC) agonist, melanotan-II (MTII), reduces food intake and body weight for hours to days after administration. One early report on the effect of MTII suggested that part of its anorexic action may be mediated by aversive consequences. In that experiment, MTII was found to support a mild conditioned taste aversion (CTA). OBJECTIVE: The present experiments replicate and extend those findings in two additional CTA paradigms to further characterize the aversive effects of MTII in rats. METHODS: Experiment 1 simultaneously assessed the ability of MTII to support CTA and reduce food intake, using a small oral infusion of a novel taste as the conditioned stimulus. Experiment 2 assessed the aversive consequences of chronic MTII administration. To accomplish this, we paired implantation of lithium chloride (LiCl)-, MTII-or saline-containing osmotic minipumps with a constantly available novel flavor. After 7 days, rats received a choice test between the minipump-paired flavor and a previously available neutral flavor. RESULTS: Rats with saline minipumps exhibited no preference for either flavor. By contrast, rats in both the LiCl and MTII minipump groups significantly preferred the neutral flavor, indicating the development of a CTA. Additionally, CTA produced by administration of MTII was found to be more resistant to extinction than that produced by LiCl. CONCLUSIONS: The reduction in food intake caused by MTII is accompanied by aversive consequences regardless of route of administration. These results present difficulties for the development of MCs-based therapies for obesity.
Introduction
The hypothalamic melanocortins (MCs) have received increasing experimental attention during the last several years. Importantly, this neuropeptide system is now thought to be critical for the regulation of food intake and energy balance. First, evidence that supports this suggestion is the finding that central administration of MC ligands produces changes in food intake. [1] [2] [3] Second, expression of MC peptides and their precursor proteins is regulated by energy balance. [4] [5] [6] [7] Third, disruption of MC signaling leads to obesity. 8 Finally, MC neurons appear to mediate the anorexic effects of the adipocyte hormone, leptin. 9 Collectively, these data suggest that the hypothalamic MC system is an important regulator of food intake and body weight. For more complete reviews of the MC system and food intake, see Cone, 10 Cone, 11 and Woods and Seeley.
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These data also suggest that pharmacotherapies based on the MC system might provide useful tools in the treatment of obesity. However, at least one potential difficulty in utilizing MC agonists as anorexic agents in humans is that the mixed MC agonist melanotan-II (MTII) reportedly produces a mild conditioned taste aversion (CTA). The general interpretation of the existence of a CTA is that the agent that caused it to develop (eg an MC agonist in this case) produces aversive effects like those of visceral illness. In a typical CTA paradigm, subjects are presented with a novel taste to sample and this is followed by the administration of the agent in question. Drugs that produce vomiting in humans and other emetic species, when used in this paradigm, generally cause a long-lasting avoidance of the novel taste to develop in both emetic and nonemetic species (eg the rat) (see Bures et al 13 for a complete review of this literature). The relevant point is that since some MC agonists have been reported to support CTAs, 1 if an agonist for the same receptor were to be developed as a pharmacotherapy for the treatment of obesity in humans, it would be important to know whether or not any potential reduction in food intake was due to the production of visceral illness. This is especially important because visceral illness is an important predictor of drug-taking compliance (eg Hoebe et al
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)
. Several recent reports have found that acute administration of the nonselective MC agonist, MTII, elicits reports of nausea and discomfort in humans. [15] [16] [17] MTII has been assessed as a potential treatment for erectile dysfunction (ED). In those studies, MTII was found to significantly improve erectile function in human males. However, men in those studies also reported experiencing nausea and visceral discomfort, as well as reduced appetite. These data would seem to suggest that peripheral administration of MTII might not be an optimal pharmaceutical intervention for ED or obesity. However, those studies employed singleor dual-administration paradigms. It remains possible that a different route of administration or a longer-term administration of MTII might result in lessened aversive consequences. The purpose of the present experiments was to assess the aversive consequences of the MC3/4 agonist, MTII, by varying the CTA paradigm and routes of drug administration. As a result of the potential therapeutic applications of MC agonists, we reasoned that some paradigms might minimize any aversive properties. That is, the development of a CTA may be specific to a central route of administration, and the first set of experiments was designed to assess this possibility. Alternatively, aversive consequences, including CTA development, may be specific to receiving an acute bolus of MTII or to the novelty of the compound. The second set of experiments was designed to assess these possibilities.
Experiment 1
The purpose of Experiment 1 was to assess the ability of MTII to support development of a CTA using singleinjection paradigms with three routes of administration. To assess whether the delivery method of MTII administration is an important factor in the development of CTA, in three separate subexperiments MTII was administered subcutanouesly (s.c.), intraperitoneally (i.p.), or intravenously (i.v.). Experiment 1a (i.p.) Rats were first habituated to 1-h daily access to water. During this hour, two bottles, each containing unflavored water, were placed on each home cage. After 12 days, all rats received two bottles containing 0.1% saccharin instead of water. Immediately following this 1-h exposure, rats received one of several doses of MTII. In Experiment 1a (i.p.), doses of MTII were 0.0, 0.3, 1.0, 3.0, and 10.0 mg/kg. MTII was dissolved in 50 mM sodium acetate/saline (pH ¼ 5.0) and administered at 1 ml/kg. On the following day, rats again received 1-h access to two bottles with unflavored tap water. On the subsequent day, a two-bottle choice test was administered in which all rats were allowed 1-h access to tap water and the saccharin solution, with the relative position of the two solutions counterbalanced across subjects. 
Subjects and materials

Results
For each test, preference ratios were calculated by dividing the amount of saccharin that was consumed on test day by the total amount of liquid consumed (ie saccharin plus water intake). Preference ratios were then subjected to one-way analysis of variance (ANOVA) using drug as the independent variable. Tukey's HSD post hoc tests were then used to compare each drug dose to vehicle.
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Experiment 1a (i.p.) MTII appeared to cause a CTA in a dose-dependent fashion. Rats that received MTII had reduced preference ratios relative to saline (Figure 1 ). Rats that received the two highest doses of MTII had significantly lower preference ratios than vehicle-treated rats (Po0.05).
Experiment 1b (i.v.) Overall, preference ratios in Experiment 1b appeared increased relative to Experiment 1a. However, MTII still appeared to cause the formation of a CTA, in a dosedependent fashion. As seen in Figure 2 , rats that received the highest i.v. doses of MTII (1 mg/kg) had preference ratios significantly lower than those of vehicle-treated controls (P'so0.05).
Experiment 1c (s.c.)
Subcutaneous administration of MTII dose-dependently reduced preference ratios relative to rats receiving vehicle. As depicted in Figure 3 , all doses of MTII (3, 10, and 30 mg/ kg) resulted in decreased saccharin intake relative to vehicle. Statistical analysis confirmed that 10 and 30 mg/kg MTIItreated rats had lower preference ratios than vehicle-treated control rats (P'so0.05).
Experiment 2a
The purpose of Experiment 2 was to assess the possible aversive quality of MTII when it is administered continuously over a 7-day period via osmotic minipump. That is, if the aversive effects of MTII are mainly short-lived and tend to subside with more chronic exposure, rats might be expected to extinguish any newly formed CTA across an entire chronic exposure period.
Methods
Phase I Animals were comparable to those used in Experiment 1. During phase 1 of the experiment, flavor 1 (0.25% grape or cherry Kool-Aid in 0.1% saccharin, counterbalanced across rats) was available ad libitum for 7 days in place of water. Following this period of adaptation to flavor 1, unflavored tap water was available for 48 h.
Surgical procedure
Osmotic minipumps that delivered 10 ml/h/day for 7 days were then implanted into the intraperitoneal cavity of all of the rats. For this procedure, the rats were briefly anesthetized 
MTII Dose
Preference Ratio * * Figure 3 Mean preference ratio (saccharin intake/total fluid intake) after s.c.
administration of MTII. *Po0.05.
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with oxygen and 3% isoflurane. Incisions were made through the skin and muscle lateral to the ventral midline. One group of rats received minipumps containing MTII to deliver a dose of 1 mg/kg/day, one group received minipumps containing lithium chloride (LiCl) to deliver a dose of 1 mmol/kg/day, and a third group received minipumps containing NaCl (0.9% w/v). The incision was closed with suture and surgical staples.
Phase II Immediately after surgery, water was removed from the home cage and replaced with flavor 2 (the alternate flavor for each rat relative to what it received in phase 1, that is, sweetened grape or cherry Kool-Aid, counterbalanced). After 7 days, all rats next received 48 h ad libitum access to unflavored tap water. Finally, all rats were given a 24-h flavor test during which flavors 1 and 2 were available without access to unflavored water. Intake of both flavors was recorded after 24 h. Body weight, food intake, and fluid intake were recorded daily throughout all phases of the experiment, and pelleted lab chow was available ad libitum throughout the experiment.
Results
Phase 1
Although no treatments were administered during phase 1, it was important to document that the groups had equivalent intakes and body weight. As expected, no differences among subsequent groups were found in these parameters. The statistical validity of these conclusions was assessed via twoway ANOVAs on (1) food intake, (2) Kool-Aid intake, and (3) body weight change. No reliable main effects or interactions were found (all P's40.10).
Phase 2
At 24 h after surgery, all rats had a decline in food intake and body weight, and then gradually regained body weight and increased their food intake until they had reached or surpassed presurgical levels. Figure 4 represents 7-day cumulative food intake (panel a) and fluid intake (panel b). During phase 2, rats with MTII minipumps consumed less food and lost more body weight than the other groups (P'so0.05). However, both LiCl-and MTII-treated groups had small reductions in Kool-Aid intake, relative to vehicletreated controls. No other significant differences were found between groups.
Two-bottle choice test
To the degree that rats developed an aversion to the flavor consumed while the minipumps were implanted, intake of that flavor would be reduced on the two-bottle test. Figure 5 represents the 24-h preference ratio (flavor 1 divided by total fluid intake). As seen in the figure, rats that had flavor 2 paired with NaCl infusion had no flavor preference. However, rats that had flavor 2 paired with LiCl infusion had a significant CTA, consuming almost their entire 24-h liquid 
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intake as flavor 1. Of particular interest were the rats that received MTII paired with flavor 2. These rats also had a preference for flavor 1 implying that MTII supported the development of a CTA. The statistical validity of these conclusions was assessed with a one-way ANOVA using drug (NaCl, LiCl, or MTII) as the independent variable. That analysis yielded a reliable main effect (F(2,17) ¼ 5.22, Po0.05. Subsequent Tukey's post hoc tests reveled that both LiCl-and MTII-treated rats had significantly lower preference ratios than vehicle-treated rats (P'so0.05).
Experiment 2b
Experiment 2b was run concurrently with Experiment 2a. The purpose of this experiment was to determine if MTII or lithium, when administered as an acute bolus, would cause an aversion to a flavor that would continue to be present for several days following the treatment; that is, would an acutely formed CTA extinguish when the flavor remained present and no further drug (MTII or lithium) were administered? Two additional groups of rats were included in the previous experiment. Until the time of surgery, they were treated identically to those rats, having tap water replaced with Kool-Aid (counterbalanced flavors) for 7 days. They then received 2 days access to tap water. However, these groups did not receive minipumps. Instead, tap water was replaced with the second Kool-Aid flavor. After 1 h, these rats received a single i.p. injection of either LiCl (0.15 M at 2% body weight) or/and s.c. injection of MTII (1 mg/kg in a volume of 2 ml/kg). As with the groups in Experiment 2a, flavor 2 remained the only source of liquid for the subsequent 7 days. Figure 6 depicts the 24-h intake data for rats in the acute drug-administration groups. We did not expect rats that had acute LiCl paired with 7 days of flavor 2 to show a preference. The left bar of Figure 6 supports the hypothesis that 7 days access to flavor 2 in the absence of LiCl was sufficient to extinguish any CTA developed on the first day. However, the results from rats that received an acute administration of MTII are more interesting. The right bar of Figure 6 represents choice-test data for rats that received a single administration of MTII on the first day of flavor 2 access. Unlike LiCl, this dose of MTII was effective at supporting the development of a CTA that was resistant to extinction, even after several days of flavor 2 access, in the absence of MTII. The statistical validity of these conclusions was assessed with two t-tests. MTII-treated rats had a significant lower preference ratio than LiCl-treated rats (t(7) ¼ 3.18, Po0.05). Further, MTII-treated rats had a significantly lower preference ratio than the 0.50% expected by chance (t(7) ¼ 4.33, Po0.05). These data support the conclusion that MTII caused a CTA that is resistant to even several days of continuous extinction treatment (ie presence of the second Kool-Aid flavor in the absence of the effects of MTII).
Experiment 3
A growing body of research demonstrates that the CNS MC system mediates the hypophagic effects of the adipocyte hormone, leptin. 4, 5, 18, 19 Thus, the MC system appears to be a key mediator of an important adiposity signal. As it seems unlikely that illness would be a primary mechanism for the target of an adiposity hormone, we sought to assess whether leptin-induced release of the endogenous MC agonist, a-MSH, would also support a CTA. To overcome the confound that exogenously administered leptin might interact with endogenous leptin, we used ob/ob mice that lack biologically active leptin. In this experiment, a large bolus of leptin was paired with a novel flavor in both wildtype and ob/ob mice. We predicted that if leptin's effects on hypothalamic POMC cells (ie MC-releasing neurons) was also aversive, a high dose of leptin would also cause CTA development.
Methods
Subjects and materials
Mice (12 ob/ob and 12 wild type) were obtained from Jackson Labs (Bar Harbor, MA, USA). They were individually housed in air flow-controlled units and maintained on regular Purina Lab Chow 5001.
Procedure All mice were trained to a 23-h water deprivation schedule until 1-h intakes reached asymptote. There were 4 training days. On the training days, the mice were given two water bottles filled with a novel flavor (20% sucrose flavored with either grape or cherry Kool-Aid). Following the 1-h access, the mice received either i.p. 10 mg/kg leptin or i.p. 0.15 M LiCl (2% body weight). After a recovery day (access to water), mice were exposed to a second novel flavor, followed by i.p. saline (2% body weight). The mice were allowed a second exposure to each flavor followed by its respective injection 
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with recovery days between exposures. Flavor pairings were counterbalanced across subjects. On the test day, all mice received access to both flavors for 24 h. The results were expressed as a preference ratio of the drug-paired flavor to total fluid intake.
Results
Figure 7 depicts data from Experiment 3. As seen in the figure, both ob/ob and wild-type mice were able to learn a CTA to a flavor paired with i.p. injection of LiCl. Consistent with previous reports, wild-type mice showed no evidence of CTA formation when the flavor was paired with leptin. Additionally, ob/ob mice also showed no evidence of CTA formation due to leptin. The statistical validity of these conclusions was assessed by two-way ANOVA using genotype (ob/ob vs wt) and paired-drug (LiCl vs leptin) as factors. This analysis yielded only a significant main effect of drug (F(1,19) ¼ 3.22, Po0.05). Subsequent Tukey's post hoc tests revealed that in both genotypes, the preference ratio was significantly lower in the LiCl-paired groups than in the leptin-paired groups (P'so0.05). No differences were found between ob/ob mice and controls.
Discussion
Interest in the hypothalamic MC system has increased dramatically during the last several years. 10 There is little disagreement that the MC system is important for the control of food intake and body weight. Indeed, most current discussions hinge only on how the MC system might exert this control and whether they mediate the effects of adiposity signals such as leptin. 20 One We also investigated the ability of MTII, delivered chronically, to support the development of a CTA to a flavor that was copresent for the duration of MTII administration. In a modification of the protocol used by Chavez et al, 22 rats received MTII (delivered via osmotic minipump) while water was replaced with Kool-Aid on the home cage. We had hypothesized that the aversive effects of MTII might be transient and, given the continuous 7-day administration, animals would come to tolerate its effects while maintaining the effect on body weight. During the subsequent 24-h test, however, rats that had the second Kool-Aid flavor paired with MTII showed a tremendous preference for the first flavor. These data indicate that MTII, even when administered chronically, is capable of supporting CTA development. Finally, test data from rats that received acute drug administration and chronic Kool-Aid exposure would appear to speak to the strength of the aversive consequences of MTII. Rats that received an i.p. bolus of LiCl and 7-day Kool-Aid access showed no preference whatsoever. This finding is consistent with our hypothesis that long-term access to Kool-Aid would extinguish any CTA that might have developed on the first day. However, rats that received an acute injection of MTII and 7-day access to Kool-Aid showed no evidence of CTA extinction. In fact, the magnitude of the CTA between chronic and acute MTII appears identical, even though the acute MTII was followed by 5-6 days recovery and opportunity for extinction. These data suggest that 1 mg/kg MTII can provide a powerful aversive stimulus. The present results have important implications for the development of pharmacotherapies for obesity that target Assessment of Melanocortin Agonist administration SC Benoit et al MC receptors. While the nature of the stimuli that caused CTA formation here has not been directly assessed, it is clear that MTII treatment was accompanied by stimuli capable of producing a powerful CTA. MTII has been administered to human males in the study of ED. While the variable of most interest in those studies was erectile function, the researchers also measured other psychological variables such as appetite and nausea. In those reports, MTII administration in humans has been described to cause frequent nausea and discomfort as well as decreased appetite. [15] [16] [17] However, men in these studies received only a single injection of larger doses of MTII than that used here. In a smaller study, repeated injections of 0.025 mg/kg MTII were also associated with mild nausea. 21 These results and those found in the present experiments call into question the utility of MTII as a treatment for obesity. Specifically, the occurrence of visceral illness and nausea during long-term and continuous administration of low doses of MTII in humans should be carefully evaluated.
